STL Volume 30 Number 6

The OX40-OX40 ligand pathway has emerged as a promising therapeutic target for moderate-to-severe atopic dermatitis, offering a novel approach that simultaneously addresses multiple inflammatory pathways involved in disease pathogenesis. This review examines phase II clinical trial data for three monoclonal antibodies targeting this pathway: amlitelimab, rocatinlimab, and telazorlimab.

Neoadjuvant cemiplimab has shown promising results for resectable cutaneous squamous cell carcinoma where surgery may result in significant morbidity. Phase 2 studies demonstrated pathological complete response rates of 51% with event-free survival of 89% at 12 months. The treatment was well-tolerated and may improve surgical outcomes by reducing tumor burden before resection, offering a valuable option for advanced disease.

Update on Guselkumab SC use (Tremfya®), Remibrutinib tablets (Rhapsido®), Pembrolizumab + berahyaluronidase alfapmph SC injection (Keytruda Qlex®), Donidalorsen SC use (Dawnzera), Garadacimab for SC use (Andembry®), and Lifileucel for IV use (Amtagvi®)